Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 5.60%
As of Wednesday, November 18, SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Tudor Pop
Michael Rose
| Share Statistics | SLS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,659.3 | $213.9 | 64% |
|
| Shares Out (Mil) | 202.4 | 55.4 | 76% |
|
| Institutional Ownership | 98.9% | 93.3% | 83% |
|
| Float (Mil) | 203.1 | 40.6 | 74% |
|
| Beta | 2.70 | 0.98 | 97% |
|
| Avg Daily Volume (000s) | 21,025 | 597 | 98% |
|
| Price Change (52-week) |
1,173% | 40.9% | 100% |
|
| Growth | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (9.9%) | (10.7%) | 29% |
|
| EPS (5yr) | 34.9% | 15.5% | 85 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (31.5%) | (15.7%) | 18% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.050) | ($0.200) | ($0.245) | |
| Month Ago EPS | ($0.050) | ($0.200) | ($0.100) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.050) | ($0.200) | ($0.100) | |
| Year/Year Chg | 0.0% | (18.7%) | (55.3%) | |
| Financials | SLS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($36) | ($44) | 19% |
|
| EPS (TTM) | ($0.203) | ($1.400) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($27) | ($34) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1,468 | $135 | 46% |
|
| Valuation | SLS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 27.62 | 1.97 | 97% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | SLS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (37.1%) | (47.5%) | 14% |
|
| ROE | (40.3%) | (51.9%) | 17% |
|
| Liabilities to Assets | 6.6% | 29.7% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
SELLAS Life Sciences Group, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors